ScreenerHero

ENSC Ensysce Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · ensysce.com
0.4294USD-0.09%Mkt Cap: 8.35M $P/E: —

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activa…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.35M USD
Enterprise Value7.55M USD
Revenue (TTM)4.50M USD
Gross Profit-7.89M USD
Net Income (TTM)-10.18M USD
Revenue/Share0.68 USD
Last Price0.4294 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.60
PEG—
EV/EBITDA—
EV/Revenue1.68
P/S1.86
P/B-8.95
EPS (TTM)-2.43
EPS (Forward)-0.05
52W Range
0.23008% of range2.750
52W High2.750 USD
52W Low0.2300 USD
Profitability
Gross Margin-175.21%
Oper. Margin-221.28%
EBITDA Margin0.00%
Profit Margin-280.48%
ROE-316.63%
ROA-136.54%
Growth
Revenue Growth-15.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.81M USD
CapEx (TTM)123.64K USD
FCF Margin-92.24%
FCF Yield-49.69%
Net Debt-479.86K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.10
Current Ratio0.70
Quick Ratio0.27
Book Value/Sh-0.05 USD
Cash/Share0.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateDec 6, 2024
Analyst Consensus
Rating—
Target (Mean)8.250 USD
Upside (mean)+1821.3%
Target Range8.250 USD – 8.250 USD
# Analysts1
Ownership
Shares Out.19.46M
Float18.54M
Insiders4.72%
Institutions4.65%
Short Interest
Short Ratio1.2d
Short % Float6.20%
Short % Out.6.20%
Shares Short1.21M
Short (prev mo.)1.14M
Technical
SMA 500.4022 (+6.8%)
SMA 2000.4838 (-11.2%)
Beta1.02
S&P 52W Chg16.45%
Avg Vol (30d)608.15K
Avg Vol (10d)272.59K
Technical Indicators
RSI (14)53.2
MACD0.0036
MACD Signal0.0074
MACD Hist.-0.0037
BB Upper0.5052 USD
BB Middle0.4363 USD
BB Lower0.3674 USD
BB Width31.59%
ATR (14)0.0389 USD
Vol Ratio (20d)0.42x